Valuation: Phytopharm plc

Market Cap 1.64Cr 2.2Cr 1.91Cr 1.8Cr 3.07Cr 211.29Cr 3.09Cr 22Cr 8.3Cr 107.19Cr 8.28Cr 8.1Cr 340.76Cr P/E 2026 *
-5.36x
P/E 2027 * -5.77x
Enterprise Value 61.54L 82.95L 71.88L 67.83L 1.15Cr 80Cr 1.16Cr 8.1Cr 3.12Cr 40Cr 3.12Cr 3.05Cr 128.22Cr EV / Sales 2026 *
0.77x
EV / Sales 2027 * 1.14x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%-4.71%-2.38%+9.18% 4.55TCr
+0.90%-0.97%+344.37%+530.72% 4.37TCr
+0.99%+2.06%+42.25%+24.22% 4.31TCr
+2.23%+0.81%+6.64%+78.50% 3.94TCr
+0.34%-4.94%+9.34%+40.23% 3.19TCr
+0.15%-2.32% - - 1.73TCr
+0.73%+0.29%+19.38%+111.62% 1.64TCr
+2.07%+0.78%+14.39%+30.91% 1.42TCr
-3.11%-3.79%+77.43%+30.02% 1.33TCr
Average +0.62%-2.97%+63.93%+106.93% 2.94TCr
Weighted average by Cap. +0.88%-3.26%+76.23%+128.04%

Financials

2026 *2027 *
Net sales 80L 1.08Cr 93.44L 88.18L 1.5Cr 103.36Cr 1.51Cr 11Cr 4.06Cr 52Cr 4.05Cr 3.96Cr 166.7Cr 90L 1.21Cr 1.05Cr 99.21L 1.69Cr 116.28Cr 1.7Cr 12Cr 4.57Cr 59Cr 4.56Cr 4.46Cr 187.54Cr
Net income -21.43L -28.89L -25.03L -23.62L -40.2L -28Cr -40.49L -2.82Cr -1.09Cr -14Cr -1.08Cr -1.06Cr -45Cr -28.01L -37.76L -32.72L -30.88L -52.54L -36Cr -52.92L -3.69Cr -1.42Cr -18Cr -1.42Cr -1.39Cr -58Cr
Net Debt -1.02Cr -1.37Cr -1.19Cr -1.12Cr -1.91Cr -131.78Cr -1.93Cr -13Cr -5.17Cr -67Cr -5.16Cr -5.05Cr -212.54Cr -61L -82.23L -71.25L -67.24L -1.14Cr -79Cr -1.15Cr -8.03Cr -3.09Cr -40Cr -3.09Cr -3.02Cr -127.11Cr
Logo Phytopharm plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!